Posted by Michael Wonder on 10 Apr 2020
EicOsis EC5026 granted fast track designation by FDA for neuropathic pain
9 April 2020 - EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble epoxide hydrolase enzyme, announced today that the U.S. FDA has granted fast track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain.
EC5026 is a first-in-class, orally administered, potent small molecule that inhibits soluble epoxide hydrolase (sEH), a key regulatory enzyme involved in the metabolism of endogenous anti-inflammatory lipid mediators. Inhibition of sEH treats pain by preventing the breakdown of these natural analgesic and anti-inflammatory fatty acids that then increase within cells to levels sufficient to treat pain.
